About: Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of lung infection in patients with cystic fibrosis: Current and future strategies Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://dx.doi.org/10.1016/j.jcf.2012.10.004
Description	In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the Major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed. (C) 2012 European Cystic Fibrosis Society. In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the Major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed. (C) 2012 European Cystic Fibrosis Society. (en)
Title	Treatment of lung infection in patients with cystic fibrosis: Current and future strategies Treatment of lung infection in patients with cystic fibrosis: Current and future strategies (en)
skos:prefLabel	Treatment of lung infection in patients with cystic fibrosis: Current and future strategies Treatment of lung infection in patients with cystic fibrosis: Current and future strategies (en)
skos:notation	RIV/00064203:_____/12:8746!RIV13-MZ0-00064203
http://linked.open...avai/predkladatel	Fakultní nemocnice v Motole
http://linked.open...avai/riv/aktivita	I
http://linked.open...avai/riv/aktivity	I
http://linked.open...iv/cisloPeriodika	6
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Dřevínek, Pavel
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice v Motole
http://linked.open...dnocenehoVysledku	175047
http://linked.open...ai/riv/idVysledku	RIV/00064203:_____/12:8746
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	pseudomonas-aeruginosa infection; resistant staphylococcus-aureus; inhaled aztreonam lysine; allergic bronchopulmonary aspergillosis; tobramycin inhalation powder; randomized controlled-trial; young-children; pulmonary-function; double-blind; stenotrophomonas-maltophilia (en)
http://linked.open.../riv/klicoveSlovo	allergic bronchopulmonary aspergillosis inhaled aztreonam lysine pseudomonas-aeruginosa infection stenotrophomonas-maltophilia tobramycin inhalation powder young-children double-blind pulmonary-function randomized controlled-trial resistant staphylococcus-aureus
http://linked.open...odStatuVydavatele	NL - Nizozemsko
http://linked.open...ontrolniKodProRIV	[4D7968969F21]
http://linked.open...i/riv/nazevZdroje	Journal of Cystic Fibrosis
http://linked.open...in/vavai/riv/obor	FC
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	43 (xsd:int)
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	11
http://linked.open...iv/tvurceVysledku	Bush, A. Dřevínek, Pavel Hjelte, L. Hoiby, N. Konstan, MW Pressler, T. Ramsey, BW Ratjen, F. Tullis, E. Wainwright, CE Cattaneo, A. Goldman, M. Bilton, D. Gartner, S. Angyalosi, G. Assael, B. Bell, S. Campbell, PW Dembowsky, K. Doering, G. Dubois, C. Eichler, I. Elborn, J. Flume, P. Foweraker, J. E Gallagher, C. Geller, D. E. Goss, C. H. Gupta, R. Heijerman, H. Henig, N. Higgins, M. Jongejan, R. Knoch, M. Muhlebach, MS Nieuwenhuizen, PW Parkins, MD Quittner, A. L. Smyth, A. Thieroff-Ekerdt, R. Vazquez, C. de Boeck, K. van der Ent, CK
http://linked.open...ain/vavai/riv/wos	000312115900001
issn	1569-1993
number of pages	19 (xsd:int)
is http://linked.open...avai/riv/vysledek of	Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

Faceted Search & Find service v1.16.116 as of Feb 22 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of Feb 22 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 82 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software